Losartan Pharmacokinetics (ADME): Absorption, Metabolism, and Clinical Implications

How Losartan Works: Mechanism of Action at the AT1 Receptor

Losartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from triggering vasoconstriction, aldosterone secretion, and sympathetic activation. This competitive antagonism lowers blood pressure without suppressing the ACE-mediated bradykinin pathway, which is why ARBs cause cough far less often than ACE inhibitors [1].

The distinction between losartan and its metabolite matters at the receptor level. Losartan itself is a competitive antagonist, while EXP3174 has substantially greater AT1-receptor potency and a longer plasma half-life [2]. Both compounds contribute to the measured response; these laboratory properties do not predict an individual patient's 24-hour blood-pressure control.

The AT1 receptor mediates major cardiovascular and renal effects of angiotensin II. AT2-receptor biology remains an active area of research, but it should not be used to promise an additional clinical benefit from losartan [3]. In the LIFE trial of 9,193 adults with hypertension and left-ventricular hypertrophy, a losartan-based regimen reduced the composite endpoint of cardiovascular death, stroke, or myocardial infarction by 13% relative to an atenolol-based regimen [4]. That trial result does not establish which molecular mechanism caused the difference.

Absorption: Oral Uptake and First-Pass Losses

Losartan is well absorbed from the gastrointestinal tract after oral administration, but systemic bioavailability reaches only about 33% because of substantial first-pass hepatic extraction [1]. Peak plasma concentrations of the parent compound appear within approximately 1 hour of dosing.

Food slows absorption modestly but does not reduce the total amount absorbed (AUC), so losartan can be taken with or without meals [1]. The FDA-approved prescribing information notes that "the pharmacokinetics of losartan and its active metabolite are linear with oral losartan potassium doses up to 200 mg" [1]. This linearity simplifies dose adjustments: doubling the dose roughly doubles plasma exposure across the approved range of 25 to 100 mg daily.

Losartan undergoes extensive presystemic metabolism. The drug is a substrate for cytochrome P450 enzymes in the liver and intestinal wall before reaching systemic circulation, and roughly 14% of the administered dose is converted to EXP3174 during this first pass [5]. The remaining parent compound that does enter the bloodstream circulates with high protein binding (98.7%, primarily to albumin) and a volume of distribution of approximately 34 liters [1].

One practical consequence of this pharmacokinetic profile: patients with significant hepatic impairment show plasma concentrations of losartan and EXP3174 that are approximately 5-fold and 1.7-fold higher, respectively, than in healthy volunteers [1]. The prescribing information recommends a starting dose of 25 mg in patients with hepatic impairment for this reason.

Distribution: Protein Binding, Volume of Distribution, and Tissue Penetration

The label reports a losartan volume of distribution of about 34 L and high plasma-protein binding for losartan and EXP3174 [1]. Those parameters describe measured pharmacokinetics; they should not be turned into a patient-specific claim about where the drug is stored.

High protein binding does not by itself establish a clinically important displacement interaction. The label reports no clinically significant interaction with warfarin and no clinically significant pharmacokinetic interaction with digoxin [1]. Patient-specific effects in severe hypoalbuminemia cannot be inferred from protein-binding percentages alone.

Losartan central nervous system penetration has been inconsistent across animal studies; early oral-dosing work found limited blood-brain-barrier crossing, while other rat experiments found functional central AT1-receptor blockade after systemic dosing [6]. The drug does cross the placenta, which is the basis for the FDA's boxed warning against use during the second and third trimesters of pregnancy due to fetal renal toxicity and death [1].

The current label says it is not known whether losartan is excreted in human milk and calls for a clinical decision about nursing or the drug because of the potential for adverse effects [1]. Protein binding alone is not enough to predict infant exposure or establish safety.

Metabolism: CYP2C9, EXP3174, and the Prodrug Question

Losartan's metabolic pathway is central to its clinical pharmacology. The parent drug undergoes oxidation primarily by CYP2C9, with a smaller contribution from CYP3A4, to produce the active carboxylic acid metabolite E-3174 (commonly called EXP3174) [5]. This metabolite accounts for about 14% of an oral dose but is responsible for most of the sustained AT1 receptor blockade.

Whether losartan qualifies as a "prodrug" has been debated. Strictly, it is not: losartan itself has intrinsic pharmacologic activity at the AT1 receptor. But its metabolite is so much more potent (10 to 40 times by receptor binding assays) and has a longer half-life (6 to 9 hours versus approximately 2 hours) that the metabolite dominates the therapeutic effect [2,7].

CYP2C9 Polymorphisms and Poor Metabolizers

The CYP2C9 gene is polymorphic. Carriers of loss-of-function alleles (CYP2C9*2 and CYP2C9*3) convert less losartan to EXP3174, resulting in higher parent drug levels and lower active metabolite exposure [8]. In CYP2C9 poor metabolizers (homozygous *3/*3, representing roughly 1 to 3% of Caucasian populations), EXP3174 formation is reduced by approximately 75% compared to extensive metabolizers [8].

CYP2C9 variants have been studied as one source of variability in losartan metabolism and blood-pressure response, but the evidence does not support a universal genotype-based dose or automatic switch. The absence of a CPIC losartan dosing guideline should not be filled with a prescriptive rule inferred from an older general pharmacogenetics paper [9,10].

Drug Interactions Affecting CYP2C9

Fluconazole, a CYP2C9 inhibitor, increased losartan exposure and decreased EXP3174 exposure in a crossover study of healthy volunteers [11]. The prescribing information reports an approximately 70% increase in losartan AUC and a roughly 40% decrease in active-metabolite AUC, while noting that the pharmacodynamic consequences were not examined [1]. A medication review is more reliable than extrapolating this result to an uncited list of other inhibitors.

Rifampin reduced losartan and active-metabolite exposure in a healthy-volunteer interaction study [12]. Because an exposure change does not quantify a patient's blood-pressure response, decisions about monitoring or changing therapy belong with the prescriber.

Elimination: Renal and Biliary Clearance Pathways

Losartan and its metabolites are eliminated through dual pathways. Approximately 35% of a dose is recovered in urine and about 60% in feces, the fecal fraction reflecting biliary excretion of both parent compound and metabolites [1].

Renal clearance of losartan is about 75 mL/min, and for EXP3174, about 25 mL/min, indicating that the metabolite is cleared more slowly [1]. Total plasma clearance of losartan is roughly 600 mL/min, consistent with significant hepatic extraction. The terminal half-life of losartan is approximately 2 hours. EXP3174 has a terminal half-life of 6 to 9 hours [1].

Renal Impairment

The current U.S. label reports that plasma concentrations and AUC values for losartan and EXP3174 increase by approximately 50% to 90% in mild or moderate renal impairment, while renal clearance decreases [1]. It does not require a dose adjustment for renal impairment alone, although volume depletion changes the starting-dose decision. Neither losartan nor EXP3174 is removed by hemodialysis. Kidney function and potassium still require clinical monitoring because renin-angiotensin-system blockade can contribute to acute kidney injury or hyperkalemia in susceptible patients [1].

Hepatic Impairment

Hepatic impairment has a more pronounced effect on losartan pharmacokinetics than renal impairment does. In patients with mild-to-moderate hepatic cirrhosis, losartan oral clearance decreased and plasma AUC values were approximately 5 times those seen in healthy volunteers [1]. The FDA label specifies a reduced starting dose of 25 mg for patients with a history of hepatic impairment. This recommendation reflects the liver's dominant role in both first-pass metabolism and biliary elimination of the drug.

Pharmacokinetic Comparison: Losartan Versus Other ARBs

Losartan's reliance on CYP2C9-mediated bioactivation distinguishes it from most other ARBs. Valsartan, for instance, has only about 20% hepatic metabolism and no active metabolite [13]. Candesartan is administered as the prodrug candesartan cilexetil, which is hydrolyzed during absorption to the active form without cytochrome P450 involvement [14]. Telmisartan undergoes glucuronidation rather than oxidative metabolism [15].

Pharmacokinetic differences among populations and genotypes can generate hypotheses, but they do not establish a universally preferred ARB. Medication selection should be based on indication, response, adverse effects, interactions, kidney function, potassium, pregnancy risk, and the treating clinician's plan [1,9].

Losartan can increase urinary uric-acid excretion through effects involving the URAT1 transporter [17]. In a post hoc LIFE analysis, the smaller rise in serum uric acid with losartan statistically accounted for an estimated 29% of the treatment difference in the primary composite endpoint, with a wide confidence interval [21]. This exploratory mediation analysis does not prove that lowering uric acid caused the cardiovascular benefit or establish losartan as gout treatment.

Dosing Informed by Pharmacokinetics

For adult hypertension, the U.S. label lists 50 mg once daily as the usual starting dose and 25 mg for possible intravascular depletion or hepatic impairment, with a total daily dose range of 25 to 100 mg [1]. Individual prescriptions may differ by indication and patient factors.

When control appears to fade before the next dose, confirm the pattern with validated home readings or ambulatory monitoring and review adherence, measurement technique, interactions, and the overall regimen. Do not split a 100 mg dose or change timing without the prescriber; any adjustment must fit the applicable label, total daily dose, kidney function, potassium level, and clinical goal.

In the RENAAL trial of 1,513 participants with type 2 diabetes and nephropathy, losartan reduced the risks of doubling of serum creatinine and end-stage renal disease relative to placebo when added to conventional antihypertensive therapy [20]. Those clinical outcomes support the labeled indication; the trial does not show that EXP3174 receptor residence time was the reason for renal benefit.

The U.S. label identifies a 25-mg starting dose for possible intravascular depletion and for mild-to-moderate hepatic impairment [1]. Age or a heart-failure label from another jurisdiction should not be added as a universal U.S. dosing rule.

Special Populations and Pharmacokinetic Considerations

Elderly Patients

In patients aged 65 and older, losartan and EXP3174 plasma concentrations are not significantly different from younger adults after correcting for renal function [1]. No age-based dose adjustment is required for hypertension. The LIFE trial enrolled patients aged 55 to 80 and demonstrated consistent benefit across age subgroups [4].

Pediatric Patients

Losartan is FDA-approved for hypertension in children aged 6 years and older. Pediatric pharmacokinetic data show similar absorption and metabolism patterns to adults, though weight-based dosing (0.7 mg/kg up to 50 mg daily) is recommended for children weighing 20 to 50 kg [1]. Limited data exist for children under age 6 or those weighing <20 kg.

Race and Ethnicity

The U.S. label states that the LIFE trial's stroke-risk benefit did not apply to Black participants, while also warning that the subgroup result is difficult to interpret [1]. Pharmacokinetic differences by race have not been studied, so the trial result should not be presented as proof of a pharmacokinetic or pharmacodynamic mechanism.